PVS1_VeryStrong: c.677G>A (last nucleotide of exon 8) produces no full-length transcript; patient mRNA analysis demonstrates complete exon 8 skipping (r.589_677del), frameshift, and NMD in two independent studies.1 PM2_Supporting: Extremely rare in population databases — gnomAD v4.1 AF = 6.23e-7 (1/1,604,126 alleles), absent from v2.1 and gnomAD-Canada, meeting VCEP threshold <0.00002.2 PP3_Supporting: SpliceAI predicts splicing impact (max delta = 0.44), meeting VCEP threshold (delta ≥0.2) for non-canonical splice position.3 PP4_Supporting: One CRC tumor from a carrier demonstrates MSI-H (5/5 markers) with loss of MLH1 protein expression by IHC.4 Evidence for pathogenicity includes confirmed RNA-level splicing aberration causing frameshift, extreme population rarity, in silico splice prediction, and tumor phenotype consistent with MMR deficiency.5
MLH1
Final classification
Pathogenic
MLH1 c.677G>A · p.Arg226Gln
MLH1
PVS1_VeryStrong: c.677G>A (last nucleotide of exon 8) produces no full-length transcript; patient mRNA analysis demonstrates complete exon 8 skipping (r.589_677del), frameshift, and NMD in two independent studies.
ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MLH1 Version 2.0.0 v2.0.0 criteria-combination framework: matched Rule4 (1 Pathogenic.Very Strong + Pathogenic.Supporting >=2) with applied criteria: PVS1 very strong, PM2 supporting, PP3 supporting, PP4 supporting, PP5 supporting; maps to Pathogenic.
Classification rationale
PVS1PM2PP3PP4PP5
Pathogenic
MLH1 c.677G>A
PVS1 + PM2 + PP3 + PP4 + PP5
→
Pathogenic
Gene diagram
· NM_000249.4 · variants mapped to exon structure
MLH1
NM_000249.4
Fetching transcript structure from UCSC…
Applied criteria · 5 met · select any tile
Met
Not met
Not assessed
N/A
Strength
very strong
supporting
Pathogenic evidence
PVS
PS
PM
PP
Benign evidence
BA
BS
BP
—
—
—
Rationale
Select a criterion.
Sources
Evidence used
Gaps remaining
Rule
—
Research & evidence
Population frequency · supports pathogenic
gnomAD v4.1
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 6.23392e-07; MAF= 0.00006%, 1/1604126 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.54082e-07; MAF= 0.00009%, 1/1170848 alleles, homozygotes = 0).
v2.1
Absent from gnomAD v2.1.
🇨🇦 CA
This variant is absent from gnomAD-Canada.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
6.2e-05%
· 1 / 1,604,126
0 hom
0 hom
European (non-Finnish) 1 / 1,170,848 |
8.5e-05% |
+ 9 not observed (Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American)
gnomAD v2.1
Absent
· 0 / ?
0 hom
0 hom
Not observed in any ancestry group.
gnomAD Canada 🇨🇦
Absent
· 0 / ?
0 hom
0 hom
Not observed in any ancestry group.
ClinVar
This variant has been reported in ClinVar as Pathogenic (18 clinical laboratories) and as Pathogenic by International Society for Gastrointestinal Hereditary Tumours (InSiGHT) (expert panel). (ClinVarID = 90318)
In silico
SpliceAI predicts possible splice impact for this variant (max delta score = 0.44). REVEL score = 0.198. BayesDel score = 0.384087. HCI prior probability for pathogenicity = 0.4702. MAPP score = 11.7. Custom PP2 score = 0.821.
Functional
Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MLH1, a DNA mismatch repair protein, is recurrently altered by deletion and mutation in various cancer types.
COSMIC
Cancer hotspots
Somatic evidence
Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV51619014, n = 7 times).
Hotspots
This variant does not lie in a statistically significant hotspot.
Literature · how each cited paper was used
4papers cited
Each card is an audit: what was searched, what was found, whether it names the variant, which criteria it fed, and why. 5 further PMIDs triaged but not cited — see Sources & References.
Novel MLH1 and MSH2 germline mutations in the first HNPCC families identified in Slovakia.
Found
Structured finding pending for this record — see source link.
Applied to
→PVS1 supports · met
Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer.
Found
Structured finding pending for this record — see source link.
Applied to
→PVS1 supports · met
RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
Found
Structured finding pending for this record — see source link.
Applied to
→PVS1 supports · met
Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.
Found
Structured finding pending for this record — see source link.
Applied to
→PP4 supports · met
→PVS1 supports · met
Sources & reference links
Triaged references · 5 PMIDs not cited in assessment
15309712 ↗
Clinical features and mismatch repair gene mutation screening in Chinese patients with hereditary nonpolyposis colorectal carcinoma.
CLINVAR
16451135 ↗
Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study).
CLINVAR
17453009 ↗
Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer.
CLINVAR
17569143 ↗
Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing.
CLINVAR
28492532 ↗
Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
CLINVAR